These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 10136547

  • 1. Reducing costs with formulary limitation of H2-receptor antagonists in a community hospital.
    Coppola P.
    Hosp Pharm; 1991 Feb; 26(2):126-9, 142. PubMed ID: 10136547
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Antiulcer therapy: an exercise in formulary management.
    Foulke GE, Siepler J.
    J Clin Gastroenterol; 1990 Feb; 12 Suppl 2():S64-8. PubMed ID: 1978846
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A practice-based approach for converting from proton pump inhibitors to less costly therapy.
    Lucas LM, Gerrity MS, Anderson T.
    Eff Clin Pract; 2001 Feb; 4(6):263-70. PubMed ID: 11769299
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Therapeutic-interchange program for oral histamine H2-receptor antagonists.
    Chase SL, Peterson AM, Wordell CJ.
    Am J Health Syst Pharm; 1998 Jul 01; 55(13):1382-6. PubMed ID: 9659966
    [Abstract] [Full Text] [Related]

  • 14. Implementing therapeutic interchange of intravenous famotidine for cimetidine and ranitidine.
    Oh T, Franko TG.
    Am J Hosp Pharm; 1990 Jul 01; 47(7):1547-51. PubMed ID: 2114789
    [Abstract] [Full Text] [Related]

  • 15. Effect of a criteria-based cost-containment program on the selection of oral H2-receptor antagonists.
    Falbe WJ, Bess DT, Capers CC, Haymond JD, Stahl AA.
    Am J Hosp Pharm; 1992 Mar 01; 49(3):632-3. PubMed ID: 1598944
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Drug-use review program for concurrent histamine H2-receptor antagonist-sucralfate therapy.
    Kane MP, Briceland LL, Garris RE, Favreau BN.
    Am J Hosp Pharm; 1990 Sep 01; 47(9):2007-10. PubMed ID: 1977317
    [Abstract] [Full Text] [Related]

  • 18. Pharmacoeconomic aspects and formulary considerations related to histamine2-receptor antagonists.
    Souney PF, Stoukides CA.
    DICP; 1989 Oct 01; 23(10 Suppl):S29-35. PubMed ID: 2573207
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Clinical appropriateness, therapeutic equivalence, and cost of conversion of H2 antagonist therapy.
    Kitrenos JG, Brown DR, Letting DJ, Rotella DL.
    Hosp Formul; 1993 Jan 01; 28(1):86-8, 91, 95-6. PubMed ID: 10123271
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.